Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Jan;37(1):15–22. doi: 10.1038/bjc.1978.2

Cellular Immunity to Encephalitogenic Factor in Man as Measured by the Macrophage Migration Inhibition Test: The Effects of Serum

D J Flavell, C W Potter
PMCID: PMC2009493  PMID: 74259

Abstract

Sensitivity to human encephalitogenic factor (EF) was measured in 70 cancer patients, in 34 patients with various non-malignant diseases and in 18 healthy volunteers, using the macrophage migration inhibition (MMI) test. Sensitization was demonstrated in 44/70 (63%) of the cancer patients, in 11/34 (32%) of the patients with non-malignant conditions and in one (5%) of the healthy individuals. No significant difference was seen in the frequency of demonstrable sensitivity with clinical stage of disease in cancer patients.

Autologous serum from cancer patients had the ability to abrogate EF-mediated migration inhibition in 22/30 sensitized individuals. This blocking occurred with a similar frequency in all 3 clinical stages of cancer. Autologous serum from patients with non-malignant disease caused abrogation of EF-mediated migration inhibition in 4/11 sensitized individuals, whilst none of the healthy control individuals showed any significant change in the migration index in the presence of autologous serum. Homologous serum from patients with carcinoma of the breast or lung with and without autologous blocking activity and serum from a healthy individual were tested against lymphocytes from patients with various tumour types with the MMI test. Of 11 patients tested in the absence of serum, 8 (73%) showed significant migration inhibition with EF, whilst serum from patients with carcinoma of the lung or breast with autologous blocking activity abolished migration inhibition with EF in all 8 individuals with the former and in 6 with the latter, regardless of the tumour type from which the lymphocytes under test were derived. Homologous serum from both a carcinoma of the lung and breast without autologous blocking activity did not abolish migration inhibition with EF, except with the latter in one patient with a carcinoma of the lung.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bray A. E., Holt P. G. Serum blocking factor as an index of metastatic spread following primary tumour excision. Eur J Cancer. 1975 Dec;11(12):855–860. doi: 10.1016/0014-2964(75)90084-5. [DOI] [PubMed] [Google Scholar]
  2. Carnegie P. R., Caspary E. A., Field E. J. Isolation of an "antigen" from malignant tumours. Br J Cancer Suppl. 1973 Aug;1:219–223. [PMC free article] [PubMed] [Google Scholar]
  3. Caspary E. A., Field E. J. Specific lymphocyte sensitization in cancer: is there a common antigen in human malignant neoplasia? Br Med J. 1971 Jun 12;2(5762):613–617. doi: 10.1136/bmj.2.5762.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coates A. S., Carnegie P. R. Immunological cross-reactivity between basic proteins of myelin and cancer. I. Lymphocyte transformation studies in immunized guinea-pigs. Clin Exp Immunol. 1975 Oct;22(1):16–21. [PMC free article] [PubMed] [Google Scholar]
  5. Currie G. A., Basham C. Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen. Br J Cancer. 1972 Dec;26(6):427–438. doi: 10.1038/bjc.1972.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Currie G. The role of circulating antigen as an inhibitor of tumour immunity in man. Br J Cancer Suppl. 1973 Aug;1:153–161. [PMC free article] [PubMed] [Google Scholar]
  7. Dickinson J. P., Caspary E. A., Field E. J. A common tumour specific antigen. I. Restriction in vivo to malignant neoplastic tissue. Br J Cancer. 1973 Feb;27(2):99–105. doi: 10.1038/bjc.1973.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dickinson J. P., Jones K. M., Aparicio S. R., Lumsden C. E. Localization of encephalitogenic basic protein in the intraperiod line of lamellar myelin. Nature. 1970 Sep 12;227(5263):1133–1134. doi: 10.1038/2271133a0. [DOI] [PubMed] [Google Scholar]
  9. Field E. J., Caspary E. A. Lymphocyte sensitisation: an in-vitro test for cancer? Lancet. 1970 Dec 26;2(7687):1337–1341. doi: 10.1016/s0140-6736(70)92361-5. [DOI] [PubMed] [Google Scholar]
  10. Field E. J., Caspary E. A. Lymphocyte sensitization in advanced malignant disease: a study of serum lymphocyte depressive factor. Br J Cancer. 1972 Jun;26(3):164–173. doi: 10.1038/bjc.1972.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ford W. H., Caspary E. A., Shenton B. Purification and properties of a lymphocyte inhibition factor from human serum. Clin Exp Immunol. 1973 Oct;15(2):169–179. [PMC free article] [PubMed] [Google Scholar]
  12. Goldstone A. H., Kerr L., Irvine W. J. The macrophage electrophoretic migration test in cancer. Clin Exp Immunol. 1973 Jul;14(3):469–472. [PMC free article] [PubMed] [Google Scholar]
  13. Hellström I., Sjögren H. O., Warner G., Hellström K. E. Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer. 1971 Mar 15;7(2):226–237. doi: 10.1002/ijc.2910070206. [DOI] [PubMed] [Google Scholar]
  14. Hughes D., Paty D. W. Lymphocyte sensitivity in cancer. Br Med J. 1971 Jun 26;2(5764):770–770. doi: 10.1136/bmj.2.5764.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Light P. A., Preece A. W., Waldron H. A. Studies with the macrophage migration inhibition (MMI) test in patients with malignant disease. Clin Exp Immunol. 1975 Nov;22(2):279–284. [PMC free article] [PubMed] [Google Scholar]
  16. McDermott J. R., Caspary E. A., Dickinson J. P. Antigen cross-reactivity in the macrophage electrophoretic mobility test. A study using cellular affinity chromatography. Clin Exp Immunol. 1974 May;17(1):103–111. [PMC free article] [PubMed] [Google Scholar]
  17. Mitchell H. Structural conformation of tumour antigen. Lancet. 1973 May 12;1(7811):1061–1061. doi: 10.1016/s0140-6736(73)90698-3. [DOI] [PubMed] [Google Scholar]
  18. Nilsson O. Immunological aspects on demyelinating diseases. Acta Neurol Scand Suppl. 1972;51:321–336. [PubMed] [Google Scholar]
  19. Rees R. C., Potter C. W. Immune response to adenovirus 12-induced tumour antigens, as measured in vitro by the macrophage migration inhibition test. Eur J Cancer. 1973 Jul;9(7):497–502. doi: 10.1016/0014-2964(73)90134-5. [DOI] [PubMed] [Google Scholar]
  20. Schlaepfer W. W. Axonal degeneration in the sural nerves of cancer patients. Cancer. 1974 Aug;34(2):371–381. doi: 10.1002/1097-0142(197408)34:2<371::aid-cncr2820340222>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  21. Shelton J. B., Potter C. W., Carr I. Cellular immunity to myelin basic protein in man and in animal model systems as measured by the macrophage migration inhibition test. Br J Cancer. 1975 May;31(5):528–534. doi: 10.1038/bjc.1975.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Singer A., Shelton J., Hill S., Potter C. Cellular immunity to human basic myelin protein in women with dysplasia and carcinoma in situ of the cervix. Br J Obstet Gynaecol. 1975 Oct;82(10):820–825. doi: 10.1111/j.1471-0528.1975.tb00580.x. [DOI] [PubMed] [Google Scholar]
  23. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES